LifeVantage FY2026 10-K: Revenue Falls 20%, Active Accounts Drop 21%, New CEO and $60M Buyback Authorized
LFVN sits 65% above its 52-week low of $3.9 on light trading volume (0.3× avg).
Summary
LifeVantage reported FY2026 revenue of $182.6M (down 20.1%) and net income of $5.1M (down 48.3%), with active accounts falling 21.2%. The 10-K also discloses a new $60M buyback, a $75M shelf registration, and a new CEO with $5.5M in equity awards.
Key Events · Earnings and Guidance · LFVN
-
FY2026 Revenue Declines 20.1%
Full-year revenue fell to $182.6M from $228.5M, with net income down 48.3% to $5.1M. Diluted EPS dropped to $0.40 from $0.75.
-
Active Accounts Shrink 21.2%
Total active accounts fell to 104,000 from 132,000. Active customers declined 24.7% to 61,000, and active independent consultants fell 15.7% to 43,000.
-
LoveBiome Acquisition Adds $9.1M Revenue
The October 2025 LoveBiome asset purchase contributed $9.1M in P84 System revenue, partially offsetting declines in Protandim, TrueScience, and LifeVantage product lines.
-
New $60M Buyback and $75M Shelf
Board authorized a new $60M stock repurchase program through December 2027, while a $75M shelf registration became effective March 20, 2026 for potential future offerings.
Analysis · LFVN · Life Sciences
The annual report confirms a steep contraction: full-year revenue fell 20.1% to $182.6 million and net income nearly halved to $5.1 million, driven by a 21.2% decline in active accounts. To stabilize, the company is pursuing the LoveBiome acquisition, a new $60 million repurchase program, and a newly hired CEO with a $5.5 million equity package. The combination of a shrinking sales force, declining customer base, and a $75 million shelf registration creates meaningful dilution and execution risk for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFVN was trading at $6.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.4M. The 52-week trading range was $3.90 to $14.28. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.